VistaGen Therapeutics Overview
- Founded
- 1998
- Status
- Public
- Employees
- 11
- Stock Symbol
- VTGN
- Investments
- 1
- Share Price
- $2.62
- (As of Thursday Closing)
VistaGen Therapeutics General Information
Description
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 343 Allerton Avenue
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
VistaGen Therapeutics Timeline
VistaGen Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.62 | $2.66 | $0.35 - $3.18 | $498M | 190M | 3.07M | -$0.26 |
VistaGen Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2020 | FY 2020 31-Mar-2020 | FY 2019 31-Mar-2019 | FY 2018 31-Mar-2018 |
|---|---|---|---|---|
| EV | 255,015 | 24,772 | 46,412 | 8,280 |
| Revenue | 648 | 0 | 0 | 0 |
| EBITDA | (14,876) | (20,698) | (24,488) | (14,254) |
| Net Income | (14,990) | (20,774) | (24,590) | (14,346) |
| Total Assets | 109,271 | 5,772 | 14,012 | 11,278 |
| Total Debt | 3,901 | 4,092 | 67 | 66 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
VistaGen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore VistaGen Therapeutics‘s full profile, request access.
Request a free trialVistaGen Therapeutics Executive Team (7)
VistaGen Therapeutics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 000000000 00.0 | VistaGen Therapeutics | Director | 000 0000 |
| 0. 000000000 | VistaGen Therapeutics | Co-Founder, President, Chief Scientific Officer & Board Member | 000 0000 |
| 0000 0000 00 | Self | Chairman | 000 0000 |
| 00000 00000 00 | VistaGen Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
VistaGen Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialVistaGen Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore VistaGen Therapeutics‘s full profile, request access.
Request a free trialVistaGen Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 00000000 | 11-May-2011 | 000000000000000000 | Other Consumer Products and Services | 00000 00000 00 |